HCFA (Health Care Financing Administration) under pressure over outpatient payment criteria
This article was originally published in Clinica
The Health Care Financing Administration (HCFA), the agency that runs the US Medicare federal health insurance plan for the elderly and disabled, says it will try to increase the number of products that can meet the new higher payment criteria under Medicare's pending prospective payment system (PPS) for hospital outpatient procedures.
You may also be interested in...
Attorneys say Sarepta did not have an obligation to report its appeal, particularly since winning a formal dispute filing with the US FDA is a long shot.
Sarepta’s Vyondys: Renal Toxicity Concerns That Delayed Approval Get Enhanced Postmarketing Scrutiny, Label Warning
Sarepta must perform enhanced pharmacovigilance for serious renal toxicity events and rhabdomyolysis with the Duchenne muscular dystrophy drug, which carries a label warning for renal toxicity. Approval letter includes 2024 target completion date for ESSENCE confirmatory trial.
Efficacy data were striking to committee members, but they want to ensure postmarketing plans gather adequate data to address safety questions.